Mechanisms of action of BCL6 during germinal center B cell development

Abstract

The transcriptional repressor B cell lymphoma 6 (BCL6) controls a large transcriptional network that is required for the formation and maintenance of germinal centers (GC). GC B cells represent the normal counterpart of most human B-cell lymphomas, which are often characterized by deregulated BCL6 expression or BCL6-mediated pathways. BCL6 suppresses gene transcription largely through recruitment of its co-repressors through its distinct repression domain. Understanding the precise biological roles of each repression domain in normal and malignant B cells is helpful for development of targeted inhibition of BCL6 functions that is emerging as the basis for design of anti-lymphoma therapies. This review focuses on recent progress in the molecular mechanisms of action of BCL6 in B cells and discusses remaining unresolved questions related to how these mechanisms are linked to normal and malignant B cell development. BCL6, germinal center, co-repressor, lymphoma Citation:Huang CX, Melnick A. Mechanisms of action of BCL6 during germinal center B cell development.

The Biological Effects of IL-21 Signaling on B-Cell-Mediated Responses in Organ Transplantation

“…BCL-6 also can control B-cell development by BTB and RD2, two molecules that repress distinct functional effects of B-cells during the germinal centers reaction. BTB is required for B-cell survival and proliferation, while RD2 might be important for the prevention of terminal B-cell differentiation (50). …”

The Eph-related tyrosine kinase ligand Ephrin-B1 marks germinal center and memory precursor B cells

“…Germinal centers (GCs) are tightly confined clusters of cells within the follicle, in which GC B cells compete for signals necessary for their survival and continued maturation into memory B cells or plasma cells. GC B cells highly express the transcription factor Bcl6 and the G protein–coupled receptor sphingosine-1-phosphate receptor (S1PR2) that promotes their confinement within the GC (Green et al, 2011; Muppidi et al, 2014; Huang and Melnick, 2015). The GC is divided into a light zone (LZ), where GC B cells interact with antigen-bearing follicular DCs (FDCs) and follicular helper T cells, and a dark zone (DZ) in which GC B cells rapidly divide and undergo somatic hypermutation (SHM).…”

Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease

“…13 Mice deficient in Bcl6 are unable to form GCs and therefore do not produce high-affinity antibodies. 14 We assessed the requirement of BCL6 expression in both donor T cells and B cells, as sources of BM-derived GC and splenic-derived TFH precursors, respectively, in a murine BO cGVHD model. 3 Furthermore, we used a small-molecule, peptidomemitic BCL6 inhibitor, 79-6, for treating established disease in both BO and sclerodermatous cGVHD models.…”